ATS 2024 Final Program

Click on the session title to view the speakers

24

SUNDAY • MAYs 19

9:35 Multi-Omic Characterization of Human Lung Development: Systems-Level Exploration of the Lung Using LungMAP 9:50 Early Airway Microbial Metagenomic and Metabolomic Signatures as Therapeutic Targets for BPD Prevention and Treatment 10:05 Objective Approaches to Multi-Dimensional Phenotyping Infants with Established BPD 10:20 Panel Question and Answer Session This session and the International Conference are supported sby an independent medical educational grant from Merck&Co., Inc. All CMEsessions have been planned and implemented in accordancewith the AccreditationCriteria of theAccreditationCouncil for ContinuingMedical Education (ACCME ® ) and are free of the control of ineligible companies (formerly commercial interests).

BASIC • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM

A11 LEVERAGING MULTI-OMICS TO ADVANCE PRECISION MEDICINE IN BRONCHOPULMONARY DYSPLASIA Assemblies on Pediatrics; Respiratory Cell and Molecular Biology 9:15 a.m. - 10:45 a.m. Marriott Marquis San Diego Marina Grand Ballroom 11-13 (Lobby Level, North Tower) Target Audience Pediatrics pulmonologists, neonatologists, clinical translational and basic researchers interested in pulmonary development and molecular mechanisms of lung injury. Objectives At the conclusion of this session, the participant will be able to: • review cutting edge -omics methods and technologies in the study of infants born preterm at risk for BPD • develop an understanding of novel insights into the molecular basis of BPD pathogenesis based on recent findings from multi-omic studies • sidentify gaps in knowledge and future directions for clinical-translational research programs that accelerate the discovery of precision therapeutics for preterm infants who are at risk for BPD Bronchopulmonary dysplasia (BPD) prevention and treatment strategies largely adhere to a “one-size-fits all approach” with little regard given to patient level-heterogeneity, differential clinical phenotypes, and anticipated variable responses to interventions. Integration of multi-omics studies provides a comprehensive understanding of molecular changes contributing to normal development, cellular response, and disease. Multi-omic approaches allow construction of comprehensive causal relationships between molecular signatures and phenotypic manifestations of a particular disease. Resulting information can be utilized to inform diagnostic, treatment, and prevention strategies including the discovery of novel biomarkers and precision therapeutics for infants and children with BPD. 9:15 Introduction 9:20 Integrated Single-Cell RNA Sequencing Across Lung Development *2024 Parker B. Francis Speaker

BEHAVIORAL • CLINICAL SCIENTIFIC SYMPOSIUM

A12 FORGOTTEN POPULATIONS: DETERMINING RESEARCH

PRIORITIES IN HISTORICALLY UNDERSTUDIED VULNERABLE COMMUNITIES Assemblies on Behavioral and Health Services Research; Health Equity and Diversity Committee 9:15 a.m. - 10:45 a.m. San Diego Convention Center Room 7A-B (Upper Level) Target Audience Clinicians practicing in pulmonary and/or critical care settings, health disparities researchers Objectives At the conclusion of this session, the participant will be able to: • identify common challenges to leading respiratory health equity research among Indigenous, SGM, and incarcerated communities • understand successful strategies for engaging underrepresented communities through community-based participatory research. • develop new strategies for implementing community-focused interventions to mitigate health disparities in Indigenous, SGM, and incarcerated communities Achieving equity in respiratory health is a key component of the ATS mission, yet large gaps exist for disparities among many

ATS 2024 Conference Program • San Diego, CA